Breast Cancer – Geographic Focus: China – Breast Cancer – China In-Depth (China)
Breast cancer is the most commonly diagnosed cancer in Chinese women. With a high incidence and prolonged treatment duration, breast cancer presents a lucrative commercial opportunity for drug manufacturers. Over the last few years, the drug-treatment rate for breast cancer in China has increased owing to the availability of novel, premium-priced, targeted therapies (e.g., pertuzumab [Roche’s Perjeta]) and the inclusion of these agents in the National Reimbursement Drug List. Based on the strong late-phase pipeline, we expect more new agents to launch for breast cancer in China during the forecast period. Additionally, in view of ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter this market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable breast cancer population, and how will drug-treatment rates change during the forecast period?·
- Which are the most commercially relevant drugs in China’s breast cancer market, and why? What are interviewed experts’ insights into current treatment options?·
- What are the market access considerations for key therapies in the breast cancer pipeline in China? What sales could these agents secure in breast cancer? What are interviewed experts’ opinions of key emerging therapies?·
- What are the key drivers and constraints in China’s breast cancer therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release date
June 2021
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology
Diagnosed incidence of breast cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations
FORECAST
10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 10+ drugs; Phase II: 10+ drugs; coverage of select Phase I products.
Table of contents
- Breast Cancer - Geographic Focus: China - Breast Cancer - China In-Depth (China)
- Breast Cancer - China In-Depth (China)
Amardeep Singh, M.Pharm., is a senior analyst on the China In-Depth team at Clarivate. He has more than nine years’ experience in market research and business analytics in the pharmaceutical industry, with expertise in market forecasting, brand performance analytics, benchmark and analogue analysis, primary market research, and competitive landscape. He has specialized in market research and competitive intelligence for a range of diseases, including NASH, colorectal cancer, acute myeloid leukemia, and non-Hodgkin’s lymphoma. He received his master’s degree in pharmaceutical management from the Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR) in New Delhi and his bachelor’s degree in pharmacy from Guru Gobind Singh Indraprastha University (GGSIPU), also in New Delhi.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux.